These include Roche's trio of drugs for treating the HER2-positive form of breast cancer, Gazyva for chronic lymphocytic leukemia, Actemra for rheumatoid arthritis, and Esbriet for the lung disease idiopathic pulmonary fibrosis.
The initial uptake of cancer immunotherapy Tecentriq has also been strong.
Roche's overall pharmaceuticals sales rose to 9.68B francs from 9.34B, while diagnostics revenues grew to 2.8B francs from 2.6B francs.
Roche reiterated that it expects FY sales to grow at a low- to mid-single-digit range at constant exchange rates and for core EPS to grow faster than revenues.
Roche also confirmed that it expects to further increase its dividend in Swiss francs.
Roche's (RHHBF) 2013 net profit rose 18% to 11.4B Swiss francs ($12.7B), missing expectations of 11.62B francs.
Core EPS +10% to 14.27 francs, falling short of consensus of 14.78 francs.
Sales +3% to 46.8B francs topping estimates of 46.7B francs.
Earnings were boosted by sales of Roche's oncology, immunology and ophthalmology products, as well as of its diagnostic offerings.
Roche plans to increase its dividend by 6% to 7.80 francs a share.
Roche forecasts that 2014 revenue will rise by a low- to mid-single-digit percentage at constant currencies and that core EPS will grow at a faster rate, with earnings boosted by sales of its biggest cancer drugs and new products. Kadcyla (breast cancer) and Gazyva (leukemia) were authorized in the U.S. last year. (PR)